Deep Blue Medical Advances, Inc. | $5,600,000 | (Apr 22, 2026)
NeoCognition | $40,000,000 | (Apr 22, 2026)
Ideally | $10,000,000 | (Apr 22, 2026)
Capstan Therapeutics
United States
- San Diego, California
- 21/03/2024
- Series B
- $175,000,000
Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The core platform technology comprises proprietary targeted lipid nanoparticles (tLNP) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. The platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com.
- Industry Biotechnology Research
- Website https://www.capstantx.com/
- LinkedIn https://www.linkedin.com/company/capstan-therapeutics/
Monk | $25,000,000 | (Apr 22, 2026)
Reliable Robotics Corporation | $160,000,000 | (Apr 22, 2026)
Humble Robotics | $24,000,000 | (Apr 22, 2026)
Sinai.ai | $1,450,000 | (Apr 22, 2026)
Qualitate | $7,000,000 | (Apr 22, 2026)
Exergy3 Limited | $13,523,900 | (Apr 22, 2026)
Syenta | $26,000,000 | (Apr 22, 2026)
urfuture | $2,299,785 | (Apr 21, 2026)
Ultralight | $9,300,000 | (Apr 21, 2026)